XP-3924

**XP-3924** is an investigational, fixed-ratio **XeriSol** co-formulation of pramlintide and regular human insulin developed by Xeris for mealtime glycemic control in **type 1 diabetes mellitus**. It combines pramlintide, an amylin analog that slows gastric emptying, suppresses postprandial glucagon secretion, and promotes satiety, with insulin human, which activates the insulin receptor to lower blood glucose. In a completed randomized Phase 2 crossover study, a single subcutaneous pre-meal dose reduced post-challenge hyperglycemia relative to regular insulin alone while providing glycemic control comparable to separately injected pramlintide plus regular insulin.

Other names

pramlintide + regular insulin